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Sodium leak channel, nonselective (NALCN) is a voltage-independent and cation-nonselective channel that is mainly responsible for
the leaky sodium transport across neuronal membranes and controls neuronal excitability. Although NALCN variants have been
conflictingly reported to be in linkage disequilibrium with schizophrenia and bipolar disorder, to our knowledge, no mutations have
been reported to date for any inherited disorders. Using linkage, SNP-based homozygosity mapping, targeted sequencing, and confirma-
tory exome sequencing, we identified two mutations, one missense and one nonsense, in NALCN in two unrelated families. The muta-
tions cause an autosomal-recessive syndrome characterized by subtle facial dysmorphism, variable degrees of hypotonia, speech impair-
ment, chronic constipation, and intellectual disability. Furthermore, one of the families pursued preimplantation genetic diagnosis on
the basis of the results from this study, and the mother recently delivered healthy twins, a boy and a girl, with no symptoms of hypo-
tonia, which was present in all the affected children at birth. Hence, the two families we describe here represent instances of loss of func-
tion in human NALCN.NALCN (MIM 611549), encoding sodium leak channel,
nonselective (NALCN), also known as voltage-gated
channel-like protein 1, extends on a large genomic region
around 363 kb in 13q33.1 (Ensembl), and contains 44
exons.1,2 Human NALCN was cloned in 1999, but its
critical role and function on nerve resting conductance,
neonatal death, and neuronal rhythm in animals were
not elucidated until recently.1–3 NALCN belongs to the
‘‘four homologous repeats of six transmembrane-spanning
segments’’ (436TM) family and acts as a TTX-resistant
leak sodium channel. Neuropeptides, substance P, and
neurotensin are able to activate NALCN through the Src
family tyrosine kinase (SFK)-dependent pathway rather
than through G-protein-coupled receptors, implicating a
unique modulation mechanism for the coupling.3,4 More-
over, NALCN is also activated similarly by M3 muscarinic
receptors in a pancreatic b cell line through G-protein-
independent and SFK-dependent mechanisms.5,6
Genetic studies have been performed in search of
human diseases associated with NALCN variants. Two
consecutive studies presented interesting results for the
putative involvement of NALCN in schizophrenia and
bipolar disorder.7,8 Although a genome-wide meta-analysis
identified an association between these diseases and
an intragenic SNP of NALCN,8 an earlier study reported
a lack of evidence of a similar association for schizo-1Department of Medical Genetics, King Faisal Specialist Hospital and Research
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The Americphrenia.7 A recent study examined 240 schizophrenic
individuals and did not find any significant association
between NALCN and treatment-resistant schizophrenia.9
A current report examined pancreatic cancer genomes
by using exome sequencing and revealed mutations in
five genes, including NALCN, indicating involvement
of axon-guidance genes in pancreatic carcinogenesis.10
Lastly, a molecular-karyotyping study reported that a
female person with congenital heart defects, facial anoma-
lies, developmental delay, and intellectual disability had a
large deletion extending from 13q33.1 to 13q34.11 The
deleted region harbors several genes, including NALCN.
We have been actively searching for genes, mutations,
and copy-number variations predisposing to autism spec-
trum disorders, intellectual disability, and dysmorphia.
We have ascertained more than 200 familial and simplex
cases under protocols approved by the King Faisal
Specialist Hospital and Research Center institutional re-
view board (IRB). A total of six individuals and their
family members from two large consanguineous families
were included in this study after IRB-approved consent
forms were obtained (Figure 1A). Individuals IV-1, V-1,
and V-2 presented with absence of speech development,
severe hypotonia, chronic constipation, global develop-
mental delay, and facial dysmorphia. Metabolic and
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Figure 1. Genetic Analysis of the Autosomal-Recessive Disorder Caused by NALCN Mutations
(A and B) Pedigrees and selected chromatograms indicating mutations and carrier status of the testedmembers of families 1 (A) and 2 (B)
are depicted. V-3 and V-4 are the outcome of preimplantation genetic diagnosis (PGD). PGDwas performed on the basis of homozygosity
mapping results, and neither individual has any NALCN mutations.
(C) Affymetrix GeneChip HumanMapping Axiom custom SNP arrays were used for genotyping, and the SNP calls were used as an input
for the AutoSNPa tool. Homozygosity analysis indicated a shared run of homozygosity in both families. The block contains 48 genes,
including NALCN.
(D) Parametric multipoint LOD score analysis was performed with the GeneHunter algorithm with Easy Linkage software. A recessive
mode of inheritance, a disease allele frequency of 0.0001%, and no phenocopies were used in the analysis. Combined linkage results
for both families indicated a single dominant peak (LOD score 5.01) on chromosome 13.gas chromatography-mass spectrometry (GC-MS) profile of
urine, an amino acid profile, a urine creatine-metabolism-
disorder panel, molecular cytogenetic arrays, and mito-
chondrial genome analysis—were normal. Using Affyme-
trix’s axiom SNP calls, our initial linkage study (as well as
screening of genome-wide loss-of-heterozygosity [LOH]
blocks among the affected individuals) revealed an approx-
imately 4.7 Mb (chr13: 98,184,670–102,934,400 Mb)
genomic interval comprising 48 genes, including NALCN
(NCBI Map Viewer Build 37.3) (Figures S1 and S2, available
online). On the basis of its function, NALCN was among
the first genes screened during our targeted sequencing
study. This revealed on exon 13 a single base deletion
(c.1489delT [p.Tyr497Thrfs*21]) (Figure S3) resulting in a
frameshift and consequently creating a stop codon (21
amino acids downstream) producing a severely truncated
protein (RefSeq accession number NM_052867.2). More-
over, we screened more than 600 (n ¼ 625) ethnically722 The American Journal of Human Genetics 93, 721–726, Octobermatched control samples. Complete segregation of the
mutation in the tested family members (n ¼ 17) and the
absence of the deletion among the control cohort sug-
gested that this alteration is not a polymorphism
(Figure 1A). The findings were then reconfirmed by exome
sequencing of individual V-1’s DNA sample.
We then identified another pedigree with the same link-
age interval (Figure 1B and Figures S4 and S5). Family 2
included three affected girls with delayed speech develop-
ment, infantile hypotonia, easily controlled seizure disor-
der, hyperactivity, chronic constipation, and cognitive
delay. Similar to in family 1, the metabolic and genetic
workups were normal. Given the shared interval, we
speculated that both families might have the same region
of shared homozygosity, and we therefore decided to
evaluate LOH blocks on chromosome 13. Using AutoSNPa,
we aligned the LOH blocks from all the affected indi-
viduals from both families, as well as remaining family3, 2013
Figure 2. Location of NALCN Mutations and Immunoblotting and NMD Analyses
(A) Coding exons of NALCN are sequentially colored with dark gray and white (upper panel). Mutations are indicated in the relevant
exons [13 and 34]). Pfam domains and low-complexity, transmembrane, coiled-coil, and unstructured regions are depicted on the
basis of the Pfam source from the Howard Hughes Medical Institute (Web Resources). The protein structure is positioned according
to the coding exons and amino acids (lower panel).
(B) Immunoblotting experiments performed on fibroblasts (from individuals V-1 and V-2) and DAOY cell lines indicated the absence
of NALCN in the affected individuals but the presence of the protein in the control cell line. 100 mg/ml of the protein was used for
immunoblotting, and b-actin was used as an internal control.
(C) qRT-PCR experiments were performed on RNA extracted from V-1’s and V-2’s fibroblasts treated with CHX (100 mg/ml) at different
periods of time (0, 8, 16, and 24 hr). Control fibroblasts and samples from affected individuals at hour 0 were not treated with CHX.
The data represent the mean fold change5 SE of three control samples and samples from two affected individuals for each time point
(each sample was run in triplicate). Compared to controls, the affected individuals showed a significant decrease in expression. *p< 0.05,
**p < 0.01 (Student’s t test).members. This analysis confirmed the shared overlapp-
ing LOH block between both families and resulted in a
region that includes NALCN (Figure 1C). Combined link-
age results for both families improved the LOD score
to 5.01 (Figure 1D). Although milder, the phenotype of
this family was similar to that in family 1. Hence, we
decided to sequence NALCN in this family as a primary
target and identified a missense mutation (c.3860G>T
[p.Trp1287Leu]) in exon 34 (Figure 2A and Figure S6).
Themutation site is highly conserved among different spe-
cies (n¼ 66, based on PolyPhen prediction) and is seated in
a region encoding the ion-transport domain and voltage-
gated potassium-channel superfamily domain. The loca-The Americtion of the mutation’s corresponding amino acid change
is indicated on a predicted three-dimensional structure of
NALCN (Figure S7).
Subsequently, we screened a large control cohort (n ¼
625) and did not find the mutation in the ethnically
matched controls. Furthermore, the mutation was not
reported in the Human Gene Mutation Database12 or
the National Heart, Lung, and Blood Institute (NHLBI)
Exome Sequencing Project Exome Variant Server (Web Re-
sources). The mutation was also not annotated in human
variation databases such as HapMap,13 the 1000 Genomes
Project,14 dbSNP, or the specialized databases for next-
generation sequencing data, such as the Next Generationan Journal of Human Genetics 93, 721–726, October 3, 2013 723
Table 1. Demographic, Clinical, and Laboratory Findings
Family 1 Family 2
IV-1 V-1 V-2 II-1 II-2 II-3
Age 7 years, 3 months 7 years, 1 month 4 years, 4 months 17 years, 6 months 16 years 9 years, 4 months
Gender male male male female female female
Age at presentation birth birth birth birth birth birth
Birth weight 2.6 kg 4 kg 2.5 kg 2.8 kg 3 kg 2.8 kg
Neonatal hypotonia severe severe severe moderate moderate mild
hypotonia severe severe severe mild mild mild
Feeding difficulties severe severe severe moderate moderate mild
Growth normal normala normala normal normal normal
Vision squint anisometropia normal normal normal squint
Hearing normal normal normal normal normal normal
Dysmorphism yes yes yes yes yes yes
Motor delay severe severe severe moderate to severe moderate to severe mild to moderate
Speech delay severe severe severe moderate to severe moderate to severe mild to moderate
Cognitive delay very severe very severe very severe severe severe severe
IQ NA NA NA 45/100 42/100 43/100
Seizure no no no yesb yesb yesb
Hyperactivity no no no yes yes yes
Constipation yes yes yes yes yes yes
Karyotype 46,XY 46,XY 46,XY 46,XX 46,XX 46,XX
Metabolic screen unremarkable unremarkable unremarkable unremarkable unremarkable unremarkable
Brain MRI normal abnormal normal normal normal normal
EEG - normal normal normalc normalc normal
EMG and NC - normal normal normal normal normal
The following abbreviations are used: EEG, electroencephalogram; EMG, electromyogram; NC, nerve conduction; and NA, not assessable.
aInitial failure to thrive.
bInfrequent and easily controlled by monotherapy.
cIntermittent activity with slow background, but no epileptic activity.Sequencing Catalog15 (Web Resources). Furthermore, we
performed an extensive in silico pathogenicity analysis
of the missense mutation by using several publicly avail-
able tools and databases, and all predicted a damaging
effect. Collectively, these results suggest that the above
identified NALCN variants in these two families are
responsible for the autosomal-recessive disorder causing
a spectrum of severe to mild hypotonia, speech delay
and impairment, and global developmental and cognitive
delay (medical histories and clinical evaluations are sum-
marized in Table 1 and are also extensively presented in
Table S1).
To examine and better understand the truncatedNALCN
expression in human tissues, we initially sought an exten-
sive in silico search by using publicly and commercially
available tools and databases. Moreover, on the basis of
previous work,1,2 it is known that Nalcn is expressed in
all brain regions and throughout the nervous system, in724 The American Journal of Human Genetics 93, 721–726, Octoberaddition to in the heart, skeletal muscle, pituitary glands,
adrenal glands, and pancreatic islet cells.1,2,5,6 Although
NALCN expression in mouse muscle was not detectable
by in situ hybridization and RNA blotting,2 we speculated
that this might be attributable to the detection power of
the techniques or species-related tissue-specific expression
of the gene. Therefore, we decided to perform RT-PCR ex-
periments on readily available RNA from control samples
and on affected individuals’ RNA from muscle and skin
biopsies taken during diagnostic procedures. These ex-
periments showed that NALCN mRNA was present in
the muscle and the fibroblasts with moderate to low
expression (data not shown). Given these results, we exam-
ined the NALCN levels in the fibroblasts of individuals V-1
and V-2 by using an immunoblotting technique, which
revealed the absence of the protein (Figure 2B). It is known
that the nonsense-mediated mRNA decay (NMD) pathway
is likely to be activated if the premature termination codon3, 2013
is located more than 50–55 nt upstream of the 30 exon-
exon junction and does not reside within either the last
exon or an exon followed by one or two exon-exon junc-
tions that exist no more than 50–55 nt downstream.16
Our mutation is positioned 74 nt before the next exon-
exon boundary, thus implicating involvement of NMD.
Therefore, we decided to measure NALCN mRNA levels
in cultured fibroblasts from individuals V-1 and V-2 by
quantitative RT-PCR (qRT-PCR). The qRT-PCR showed a
significant reduction ofNALCNmRNA in the affected indi-
viduals (n ¼ 2) compared to controls (n ¼ 3), consistent
with the NMD. We next performed similar qRT-PCR
experiments on individuals’ fibroblasts treated with cyclo-
heximide (CHX) and control fibroblasts without CHX
treatments. The treatment recovered the reduced expres-
sion of NALCN in the affected individuals’ fibroblasts
(Figure 2C).
Family 1 decided to go through preimplantation genetic
diagnosis (PGD) at our hospital. PGD was solely done
on the basis of the genetic analysis using the informa-
tion from our study. The mother recently delivered
healthy normal twins, a boy and girl, with no symptoms
of hypotonia, which was present from birth in the
affected boys in this family. Postnatal DNA analysis of
NALCN from the twins confirmed their normal status
(Figure 1A).
NALCN, unlike other members of the 436TM voltage-
gated-channel family (comprising 21 members2,17), is
noninactivating and voltage independent and has the
capacity to be a cation-nonselective channel permeable
to sodium, potassium, and calcium. These features have
been attributed to the fewer positive charges in the
voltage-sensing S4 segment, one of the six a-helical trans-
membrane segments (S1–S6) belonging to each of four
homologous domains, which normally contain more
positively charged amino acid residues.2–4,18 The channel
becomes very important in that it not only is an elusive
background leakage for Naþ currents at synapses but also
has the ability to stimulate firing action potentials with
the help of substance P and neurotensin.2–4 These unique
structural and biochemical properties in animals are likely
to be preserved in humans given the high interspecies
conservation (99% homology between rat and human
NALCN). In our individuals in family 1, the single-base
deletion leads to a radically truncated protein lacking
both three of four ion-transport domains and the same
number of voltage-gated potassium-channel superfamily
domains, which are highly conserved among different
species. As a result, the abnormal protein is obviously
incompatible with the typical function of NALCN. There-
fore, it is conceivably safe to speculate that, just as in the
knockout mouse that showed a severe phenotype and
was unable to reach the second day of life, such a drasti-
cally truncated channel will have severe phenotypic con-
sequences, as seen in our affected individuals, because of
(1) a significantly reduced capacity of the permeability of
the channel and (2) the consequent accumulation of cat-The Americions (specifically Naþ ions); together, these will lead to
an imbalance in the maintenance of nerve resting poten-
tials and hence create a disturbance in neuronal conduc-
tance. However, the missense mutation is predicted to be
sitting on a site probably close to the outer region of the
channel (Figure S7) and is therefore likely to have lesser
functional consequences; hence, it might be attributed
to the milder phenotype seen in the affected individuals
from family 2. Intriguingly, in addition to displaying
mild to severe hypotonia, global developmental, and
speech delay, all the affected individuals from both
families presented with chronic constipation. It is known
that NALCN is highly expressed in the murine small intes-
tine19 and, together with substance P, is involved in
induced depolarization of pacemaking activity of inter-
stitial cells of Cajal in the gastrointestinal muscles.19
Therefore, disturbed pacemaking activity due to
NALCN mutations might be related to such symptoms as
seen in our affected individuals. Although more work
needs to be done for better understanding the link
between the NALCN mutations and the phenotypic
consequences in these individuals, we believe NALCN’s
involvement in an inherited human disease will open
new venues for research and continue to be a subject of
further studies.Supplemental Data
Supplemental Data include seven figures and one table and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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